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8It has been known for many  years that high levels of fetal
hemoglobin (Hb F) have an important clinical beneﬁt in
patients with sickle cell anemia (SCA). This knowledge was
initially based on the observation that populations of Indian
and Arabian SCA patients with high Hb F levels have a milder
clinical form of the disease.1 Later on, epidemiological stud-
ies demonstrated that patients with Hb F levels above 20%
had consistently lower rates of recurrent clinical events such
as vaso-occlusive crises, acute chest syndrome and hospi-
talizations, and patients with Hb F levels above 10% had
reduced occurrence of aseptic necrosis and strokes.2 A sig-
niﬁcant increase of 1.0 g/dL in hemoglobin levels in the high
Hb F group was also noted, indicating a reduction in the rate
of hemolysis.2 A study of life expectancy in sickle cell disease
(SCD) patients demonstrated an improved survival of patients
with Hb F levels above 8.6% and an increased risk of early death
in patients with low Hb F levels.3
The presence of Hb F in red blood cells (RBCs) alters contact
between RBCs with hemoglobin S (Hb S) and inhibits the for-
mation of polymers in deoxygenated RBCs. Hb F is produced
by a fraction of RBCs denominated F-cells, which contain vari-
able concentrations of Hb F.4 Studies suggest that when F-cells
contain around 10 pg of Hb F there is complete inhibition of
polymer formation even when oxygen saturation is from 40%
to 70%.5 F-cells are RBCs that have a much longer survival
than non-F-cells, with their survival being related to their Hb
F content: the higher the Hb F content the longer the life span
of F-cells.6 The survival of non-F-cells is inversely correlated
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reserved.to the percentage of F-cells, possibly because patients with
higher Hb F levels have better spleen function and thus have
more efﬁcient removal of non-F-cells from the circulation.
In the current issue of the Revista Brasileira de Hema-
tologia e Hemoterapia, there is an article entitled “Pattern of
hemolysis parameters and association with fetal hemoglobin
in sickle cell anemia patients in steady state” by Moreira
et al.7 In this article the authors demonstrate the beneﬁ-
cial effects of elevated Hb F levels on hemolysis markers
in SCA patients. When patients achieved Hb F levels above
10% they presented with signiﬁcant reductions in reticulocyte
counts and lactate dehydrogenase (LDH) levels. This increase
in Hb F levels was achieved by treatment using hydroxyurea
at doses that ranged from 0.5 to 1.5 g/day. Reduction of the
rate of hemolysis in SCA patients is of vital importance in
the prognosis of these patients. An observational multicen-
ter study of 415 SCA patients who were followed-up for a
median of 2.4 years reported that patients with an hemolytic
component (assessed by measuring LDH, aspartate amino-
transferase, total bilirubin and reticulocyte count) in the upper
tertile presented over three times greater risk of death (Haz-
ard ratio of 3.44).8 Furthermore, the hemolytic component
was positively associated with higher systemic pulse pressure,
serum N-terminal pro-brain natriuretic peptide (NT-proBNP)
concentration, tricuspid regurgitation velocity and severaldical School, Av. Bandeirantes, 3900, 14049-900 Ribeirão Preto,
other cardiac side effects. There was also an inverse correla-
tion between the rate of hemolysis and oxygen saturation as
measured by pulse oximetry, which persisted after adjustment
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or hemoglobin concentration; patients on hydroxyurea ther-
py presented a signiﬁcantly lower hemolytic component.8
Moreira et al.7 also demonstrated that hydroxyurea ther-
py and subsequent elevation of Hb F levels was associated
o reductions in arginase I levels. The lowest arginase I lev-
ls were seen in patients taking hydroxyurea at doses greater
han 20 mg/kg/day. Arginase I is an enzyme that metabolizes
-arginine, the precursor of nitric oxide (NO). Therefore, the
ncreased levels of arginase I seen in SCA patients contribute to
 reduction in NO concentration. The ﬁndings of this study are
n agreement with a previous study in which SCD patients on
ydroxyurea therapy presented signiﬁcantly lower arginase
ctivity and higher NO synthase activity; a direct correlation
etween Hb F levels and the decrease in arginase activity
as also observed.9 These important ﬁndings indicate that
ydroxyurea may have a beneﬁcial effect in reducing arginase
 levels and in the production of NO.
onﬂicts  of  interest
he authors declare no conﬂicts of interest.
 e  f  e  r  e  n  c  e  s. Perrine RP, Pembrey ME, John P, Perrine S, Shoup F. Natural
history of sickle cell anemia in Saudi Arabs. A study of 270
subjects. Ann Intern Med. 1978;88(1):1–6.
9 1 5;3  7(3):148–149 149
. Powars DR, Weiss JN, Chan LS, Schroeder WA. Is there a
threshold level of fetal hemoglobin that ameliorates morbidity
in sickle cell anemia? Blood. 1984;63(4):921–6.
. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg
MH, et al. Mortality in sickle cell disease. Life expectancy and
risk factors for early death. N Engl J Med. 1994;330(23):
1639–44.
. Steinberg MH, Chui DH, Dover GJ, Sebastiani P, Alsultan A.
Perspectives. Fetal hemoglobin in sickle cell anemia: a glass
half full? Blood. 2014;123(4):481–5.
. Maier-Redelsperger M, Noguchi CT, de Montalembert M,
Rodgers GP, Schechter AN, Gourbil A, et al. Variation in fetal
hemoglobin parameters and predicted hemoglobin S
polymerization in sickle cell children in the ﬁrst two  years of
life: Parisian Prospective Study on Sickle Cell Disease. Blood.
1994;84(9):3182–8.
. Franco RS, Yasin Z, Palascak MB, Ciraolo P, Joiner CH,
Rucknagel DL. The effect of fetal hemoglobin on the survival
characteristics sickle cells. Blood. 2006;108(3):1073–6.
. Moreira JA, Laurentino MR, Machado RP, Barbosa MC,
Gonc¸alves RP, Mota AM, et al. Pattern of hemolysis parameters
and association with fetal hemoglobin in sickle cell anemia
patients in steady state. Rev Bras Hematol Hemoter.
2015;37(3):167–71.
. Nouraie M, Lee JS, Zhang Y, Kanias T, Zhao X, Xiong Z, et al.
The relationship between the severity of hemolysis, clinical
manifestations and risk of death in 415 patients with sickle
cell anemia in the US and Europe. Haematologica.
2013;98(3):464–72.. Iyamu EW, Cecil R, Parkin L, Woods G, Ohene-Frempong K,
Asakura T. Modulation of erythrocyte arginase activity in sickle
cell disease patients during hydroxyurea therapy. Br J
Haematol. 2005;131(3):389–94.
